Effects of Nicotine on Urinary Bladder Carcinogenesis.
Level 5 - mechanism / opinion, no new human data
Narrative review of bench and animal studies with no direct human clinical data.
PubMed 42458916 · doi:10.1111/pin.70151
What was done
This review summarized experimental literature examining the role of nicotine and its metabolite cotinine in urinary bladder carcinogenesis, drawing from two-stage rat carcinogenesis models and in vitro mechanistic studies of receptor signaling and cell proliferation.
What was found
The abstract reports no numerical values, sample sizes, or effect estimates. Qualitatively, in a two-stage rat model, nicotine administration increased the incidence and multiplicity of invasive urothelial carcinoma after initiation, whereas nicotine alone caused hyperplasia without tumor formation. Mechanistically, nicotine stimulated urothelial proliferation via α7 nicotinic acetylcholine receptor (nAChR) activation (triggering STAT3 and ERK1/2 pathways) and through cytotoxicity followed by regenerative proliferation. Cotinine induced proliferation via nAChRs without causing cytotoxicity.
Why it matters
This work identifies nicotine as a biological tumor-promoting agent rather than a passive component in tobacco, demonstrating that it can facilitate bladder cancer progression independently of classical DNA-reactive carcinogens in experimental models.
Limits
No quantitative data, animal counts, or statistical metrics are provided in the abstract. The conclusions rely on animal models and in vitro mechanisms, which may not directly reflect human bladder tissue kinetics, exposure routes, or clinical risk in isolation from whole tobacco smoke.
Cited by
- supports Nicotine itself is not carcinogenic.